These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26457798)

  • 1. Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis.
    Lage DP; Martins VT; Duarte MC; Garde E; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
    Parasite Immunol; 2015 Dec; 37(12):646-56. PubMed ID: 26457798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.
    Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA
    Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
    Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
    Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis.
    Martins VT; Chávez-Fumagalli MA; Lage DP; Duarte MC; Garde E; Costa LE; da Silva VG; Oliveira JS; Magalhães-Soares DF; Teixeira SM; Fernandes AP; Soto M; Tavares CA; Coelho EA
    PLoS One; 2015; 10(9):e0137683. PubMed ID: 26367128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection.
    Ribeiro PAF; Dias DS; Lage DP; Martins VT; Costa LE; Santos TTO; Ramos FF; Tavares GSV; Mendonça DVC; Ludolf F; Gomes DA; Rodrigues MA; Chávez-Fumagalli MA; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
    Mol Immunol; 2019 Feb; 106():108-118. PubMed ID: 30594673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new Leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis.
    Martins VT; Lage DP; Duarte MC; Costa LE; Garde E; Rodrigues MR; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
    Acta Trop; 2016 Feb; 154():73-81. PubMed ID: 26593442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
    Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
    Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
    Ribeiro PAF; Dias DS; Lage DP; Costa LE; Martins VT; Tavares GSV; Mendonça DVC; Lima MP; Oliveira JS; Steiner BT; Machado-de-Ávila RA; Roatt BM; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Teixeira AL; Coelho EAF
    Cell Immunol; 2018 Sep; 331():67-77. PubMed ID: 29871740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
    Ribeiro PAF; Vale DL; Dias DS; Lage DP; Mendonça DVC; Ramos FF; Carvalho LM; Carvalho AMRS; Steiner BT; Roque MC; Oliveira-da-Silva JA; Oliveira JS; Tavares GSV; Galvani NC; Martins VT; Chávez-Fumagalli MA; Roatt BM; Moreira RLF; Menezes-Souza D; Oliveira MC; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
    Cytokine; 2020 May; 129():155031. PubMed ID: 32062145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with a CD4
    Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
    Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
    Agallou M; Margaroni M; Karagouni E
    Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis.
    Dias DS; Ribeiro PAF; Martins VT; Lage DP; Portela ÁSB; Costa LE; Salles BCS; Lima MP; Ramos FF; Santos TTO; Caligiorne RB; Chávez-Fumagalli MA; Silveira JAG; Magalhães-Soares DF; Gonçalves DU; Oliveira JS; Roatt BM; Duarte MC; Menezes-Souza D; Silva ES; Galdino AS; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
    Mol Immunol; 2017 Nov; 91():272-281. PubMed ID: 28988041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice.
    Santos TTO; Martins VT; Lage DP; Costa LE; Salles BCS; Carvalho AMRS; Dias DS; Ribeiro PAF; Chávez-Fumagalli MA; Machado-de-Ávila RA; Roatt BM; de Magalhães-Soares DF; Menezes-Souza D; Coelho EAF; Duarte MC
    Acta Trop; 2017 Jul; 171():8-16. PubMed ID: 28288798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.
    Costa LE; Goulart LR; Pereira NC; Lima MI; Duarte MC; Martins VT; Lage PS; Menezes-Souza D; Ribeiro TG; Melo MN; Fernandes AP; Soto M; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    PLoS One; 2014; 9(10):e110014. PubMed ID: 25333662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.
    Martins VT; Chávez-Fumagalli MA; Costa LE; Canavaci AM; Martins AM; Lage PS; Lage DP; Duarte MC; Valadares DG; Magalhães RD; Ribeiro TG; Nagem RA; Darocha WD; Régis WC; Soto M; Coelho EA; Fernandes AP; Tavares CA
    PLoS Negl Trop Dis; 2013; 7(3):e2148. PubMed ID: 23573301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis.
    Dias DS; Martins VT; Ribeiro PAF; Ramos FF; Lage DP; Tavares GSV; Mendonça DVC; Chávez-Fumagalli MA; Oliveira JS; Silva ES; Gomes DA; Rodrigues MA; Duarte MC; Galdino AS; Menezes-Souza D; Coelho EAF
    Parasitology; 2018 May; 145(6):740-751. PubMed ID: 29113597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis.
    Ribeiro PAF; Dias DS; Novais MVM; Lage DP; Tavares GSV; Mendonça DVC; Oliveira JS; Chávez-Fumagalli MA; Roatt BM; Duarte MC; Menezes-Souza D; Ludolf F; Tavares CAP; Oliveira MC; Coelho EAF
    Cytokine; 2018 Nov; 111():131-139. PubMed ID: 30142534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.